Special Issue "Non-Coding RNAs as Emerging Regulators of Signalling Pathways and Novel Therapeutic Targets in Human Cancers"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 31 March 2020.

Special Issue Editors

Prof. Dr. Martin Pichler
E-Mail Website
Guest Editor
Research Unit of Non-Coding RNA and Genome Editing, Division of Oncology, Medical University of Graz, 8010 Graz, Austria
Interests: Cancer Research; Non-coding RNAs; Uro-gential cancers; Gastrointestinal cancers; Breast Cancer
Prof. Dr. Tony Gutschner
E-Mail Website
Co-Guest Editor
Medical Faculty, Martin-Luther-University Halle-Wittenberg, Charles Tanford Protein Centre (1st Floor, R.1.07), Kurt-Mothes-Str. 3a, 06120 Halle (Saale), Germany
Interests: cancer biology; metastasis; non-coding RNAs; RNA-binding proteins; functional genomics; genome engineering; CRISPR/Cas9
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer is a devastating disease responsible for millions of deaths every year around the world. While mainly considered a genetic disease, epigenetic and post-transcriptional mechanisms emerged as significantly contributors to cancer development and progression.

The field of non-coding RNA research in cancer evolved about 20 years ago with the discovery of small regulatory non-coding RNAs called microRNAs. More recently, the class of long non-coding RNAs (lncRNAs), defined by RNA transcripts longer than 200 nucleotides in length with no open reading frame, has received much attention in the field of cancer biology. In fact, several lncRNAs have been shown to be not only dysregulated in different types of cancers but also function as direct effectors or mediators for many cancer signalling pathways. Hence, lncRNAs play a role in the regulation of cellular processes such as genome integrity, chromatin organization and gene expression control, translation regulation as well as signal transduction. The purpose of this Special Issue is to bring together a series of articles (both reviews and original research) from experts of non-coding RNA research that highlight the history and broaden our current understanding of the role of non-coding RNAs (both small and long) in cancer and their impact on signalling pathways. We invite contributions describing the role of non-coding RNAs in cancer development, cell fate decision as well as cell-cell communication, and immune evasion. In addition, manuscripts discussing state-of-the-art ncRNA technologies and developments in diagnostics and therapeutics of non-coding RNAs are invited as well.

Prof. Dr. Martin Pichler
Prof. Dr. Tony Gutschner
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle
The Landscape of Long Non-Coding RNA Dysregulation and Clinical Relevance in Muscle Invasive Bladder Urothelial Carcinoma
Cancers 2019, 11(12), 1919; https://doi.org/10.3390/cancers11121919 - 02 Dec 2019
Abstract
Bladder cancer is one of the most common cancers in the United States, but few advancements in treatment options have occurred in the past few decades. This study aims to identify the most clinically relevant long non-coding RNAs (lncRNAs) to serve as potential [...] Read more.
Bladder cancer is one of the most common cancers in the United States, but few advancements in treatment options have occurred in the past few decades. This study aims to identify the most clinically relevant long non-coding RNAs (lncRNAs) to serve as potential biomarkers and treatment targets for muscle invasive bladder cancer (MIBC). Using RNA-sequencing data from 406 patients in The Cancer Genome Atlas (TCGA) database, we identified differentially expressed lncRNAs in MIBC vs. normal tissues. We then associated lncRNA expression with patient survival, clinical variables, oncogenic signatures, cancer- and immune-associated pathways, and genomic alterations. We identified a panel of 20 key lncRNAs that were most implicated in MIBC prognosis after differential expression analysis and prognostic correlations. Almost all lncRNAs we identified are correlated significantly with oncogenic processes. In conclusion, we discovered previously undescribed lncRNAs strongly implicated in the MIBC disease course that may be leveraged for diagnostic and treatment purposes in the future. Functional analysis of these lncRNAs may also reveal distinct mechanisms of bladder cancer carcinogenesis. Full article
Show Figures

Figure 1

Review

Jump to: Research

Open AccessReview
Current Concepts of Non-Coding RNAs in the Pathogenesis of Non-Clear Cell Renal Cell Carcinoma
Cancers 2019, 11(10), 1580; https://doi.org/10.3390/cancers11101580 - 17 Oct 2019
Abstract
Renal cell carcinoma (RCC) is a relatively rare malignancy of the urinary tract system. RCC is a heterogenous disease in terms of underlying histology and its associated underlying pathobiology, prognosis and treatment schedule. The most prevalent histological RCC subtype is clear-cell renal cell [...] Read more.
Renal cell carcinoma (RCC) is a relatively rare malignancy of the urinary tract system. RCC is a heterogenous disease in terms of underlying histology and its associated underlying pathobiology, prognosis and treatment schedule. The most prevalent histological RCC subtype is clear-cell renal cell carcinoma (ccRCC), accounting for about 70–80% of all RCCs. Though the pathobiology and treatment schedule for ccRCC are well-established, non-ccRCC subtypes account for 20%–30% of RCC altogether, and their underlying molecular biology and treatment options are poorly defined. The class of non-coding RNAs—molecules that are generally not translated into proteins—are new cancer drivers and suppressors in all types of cancer. Of these, small non-coding microRNAs (miRNAs) contribute to carcinogenesis by regulating posttranscriptional gene silencing. Additionally, a growing body of evidence supports the role of long non-coding RNAs (lncRNAs) in cancer development and progression. Most studies on non-coding RNAs in RCC focus on clear-cell histology, and there is a relatively limited number of studies on non-ccRCC subtypes. The aim of this review is to give an overview of the current knowledge regarding the role of non-coding RNAs (including short and long non-coding RNAs) in non-ccRCC and to highlight possible implications as diagnostic, prognostic and predictive biomarkers. Full article
Show Figures

Figure 1

Back to TopTop